BridgeMD
Tests treatment safety and results for Carcinoma, Hepatocellular
Official title Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
ClinicalTrials.gov ID: NCT06794073
What this study is testing
- What it's testing
- This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age 18-80 years, regardless of gender.
- Clinically or pathologically confirmed HCC.
- CNLC stage IIb-IIIa, deemed unresectable after multidisciplinary evaluation.
- Having radiologically evaluable, untreated target lesions for ablation, with the largest diameter of the target tumor \>5 cm.
- Patients who have not undergone systemic chemotherapy, targeted therapy, or immunotherapy for hepatocellular carcinoma, or those who have been...
You likely can't join if
- Child-Pugh class C liver dysfunction.
- Tumor thrombus in the main portal vein or hepatic vein.
- Extensive metastatic disease with an expected survival \<3 months.
- Severe dysfunction of major organs (liver, kidney, heart, lung, or brain).
- History of esophageal/gastric variceal bleeding within the past month.
- History of other malignancies.
See the full eligibility criteria
- Age 18-80 years, regardless of gender.
- Clinically or pathologically confirmed HCC.
- CNLC stage IIb-IIIa, deemed unresectable after multidisciplinary evaluation.
- Having radiologically evaluable, untreated target lesions for ablation, with the largest diameter of the target tumor \>5 cm.
- Patients who have not undergone systemic chemotherapy, targeted therapy, or immunotherapy for hepatocellular carcinoma, or those who have been evaluated as SD (stable disease) or PD (progressive disease) after...
- ECOG PS 0-1 and an expected survival \>3 months.
- Child-Pugh score ≤7.
- Child-Pugh class C liver dysfunction.
- Tumor thrombus in the main portal vein or hepatic vein.
- Extensive metastatic disease with an expected survival \<3 months.
- Severe dysfunction of major organs (liver, kidney, heart, lung, or brain).
- History of esophageal/gastric variceal bleeding within the past month.
- History of other malignancies.
- Last anti-tumor therapy (e.g., radiotherapy, systemic chemotherapy, or local treatment) within \<1 month.
- Active infection; HBV co-infection (HBV DNA ≥2000 IU/mL or ≥10⁴ copies/mL unless reduced by one log after antiviral therapy); HCV co-infection requiring guideline-directed antiviral treatment; HIV infection; or biliary...
- History of organ transplantation or hepatic encephalopathy.
- Uncorrectable coagulation disorders.
- Refractory massive ascites, pleural effusion, or cachexia.
- Pregnancy, impaired consciousness, or inability to comply with treatment.
- High tumor burden (sum of the largest liver lesion diameter and number of liver lesions \>12).
- Any other condition deemed unsuitable by investigators that may affect study participation.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.